Hodgkin Lymphoma: The Basics
This article provides basic information about Hodgkin lymphoma, how it is diagnosed and how it is treated.
This article provides basic information about Hodgkin lymphoma, how it is diagnosed and how it is treated.
An overview of surgical procedures used in the diagnosis and treatment of Hodgkin lymphoma.
This article provides information and staging and treatment of Hodgkin Lymphoma.
Brentuximab vedotin is an antibody conjugate (an antibody with a cell-killing medication attached to it) directed against a protein called CD30, found on the surface of some lymphoma cells. Antibodies, which are normally found in the body, are developed by the immune system to destroy foreign material (such as a germ). Brentuximab vedotin is a manmade antibody that causes the immune system to attack lymphoma cells that have the CD30 protein on them. In addition, the drug has an agent attached to it that disrupts functions critical to cell growth and, in turn, causes cell death.
Carmustine kills cancer cells through a process called alkylation. Alkylation damages the DNA of cells, which prevents them from dividing and causes them to die. Since cancer cells, in general, divide faster and with less error correcting than healthy cells, cancer cells are more sensitive to this damage.
A late effect is a side effect related to a cancer diagnosis or treatment that happens months to years after treatment. This article provides information about possible late effects after radiation treatment for Hodgkin lymphoma.
Danielle Land, CRNP provides a review of the treatment of Hodgkin lymphoma, and symptom management and survivorship concerns for patients.
Hodgkin Lymphoma requires complex symptom management and an understanding of survivorship issues relevant to these patients.
There are a variety of treatments currently available for Hodgkin Lymphoma patients. Learn about the exciting progress in Hodgkin Lymphoma treatment from this insightful video presentation.